Ads
related to: rna polymerase i inhibitor treatment
Search results
Results From The WOW.Com Content Network
Tenofovir DF was the first nucleotide reverse-transcriptase inhibitor approved by the FDA for the treatment of HIV-1 infection in October 2001. [ 18 ] [ 23 ] Table 4 A schematic overview of the approved NRTIs and NtRTI and their corresponding endogenous deoxynucleosides and deoxynucleotide.
The protein is an RNA-dependent RNA polymerase, which means that it uses single-stranded RNA as a template to form double-stranded RNA . [14] It contains 591 amino acids with the last 21 amino acids at the C-terminal end functioning as a cell membrane anchor that is hydrophobic in nature.
The duration of treatment is typically 12 weeks. [14] [15] ... which is the viral RNA polymerase, thus acts as an inhibitor of viral RNA synthesis. [28]
RNA polymerase 1 (also known as Pol I) is, in higher eukaryotes, the polymerase that only transcribes ribosomal RNA (but not 5S rRNA, which is synthesized by RNA ...
Rifampicin inhibits bacterial RNA polymerase, and is commonly used to inhibit the synthesis of host bacterial proteins during recombinant protein expression in bacteria. RNA encoding for the recombinant gene is usually transcribed from DNA by a viral T7 RNA polymerase, which is not affected by rifampicin. [citation needed]
The main types of RNA therapeutics are those based on messenger RNA (mRNA), antisense RNA (asRNA), RNA interference (RNAi), and RNA aptamers. Of the four types, mRNA-based therapy is the only type which is based on triggering synthesis of proteins within cells, making it particularly useful in vaccine development. [ 3 ]
[1] [2] Bemnifosbuvir is the orally bioavailable hemisulfate salt of AT-511, which is metabolized in several steps to the active nucleotide triphosphate AT-9010, acting as an RNA polymerase inhibitor and thereby interfering with viral replication.
Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. [1] While it showed promise in early clinical trials, [2] [3] poor results in Phase IIb trials led to it being discontinued from development for treatment ...
Ad
related to: rna polymerase i inhibitor treatment